At the 30th Annual Miami Breast Cancer Conference, Lisa Carey, MD, presented the major questions in managing triple-negative breast cancer. This type of breast cancer makes up approximately 15% of all breast cancer cases, is typically more aggressive, and has a higher risk of early relapse.
How best to manage patients who present with ductal carcinoma in situ (DCIS), a noninvasive and early form of breast cancer, remains unclear. Treatment options range from minimal, breast-conserving surgical intervention and no follow-up treatment, to surgical intervention followed by additional treatment.
Risk factors for breast cancer can be parsed into genetic and biological factors, and environmental and lifestyle factors; and the general consensus is that screening and prevention strategies should be tailored based on an individual’s risk assessment.
Most breast cancer patients are treated with some form of chemotherapy, and because women with breast cancer are now surviving longer, the long-term effects of chemotherapy have become a major issue.
New technologies and techniques are in development to use blood samples to detect biological material in the blood that can differentiate a patient with cancer from one who does not have cancer and to aid in the treatment of breast cancer patients.
As part of our coverage for the 30th Annual Miami Breast Cancer Conference, we bring you an interview with Dr. Mark Pegram, director of the breast cancer program at the Stanford Women’s Cancer Center and codirector of the molecular therapeutics program. Dr. Pegram will be discussing the potential for novel HER2 combination therapies at the conference.